Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
XRAY Quote, Financials, Valuation and Earnings
Last price:
$12.54
Seasonality move
:
6.08%
Day range:
$12.33 - $12.78
52-week range:
$9.85 - $19.27
Dividend yield:
5.11%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
1.69x
Volume:
6.8M
Avg. volume:
4.5M
1-year change:
-34.04%
Market cap:
$2.5B
Revenue:
$3.8B
EPS (TTM):
-$4.43
Analysts' Opinion
-
Consensus RatingDentsply Sirona, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.23, Dentsply Sirona, Inc. has an estimated upside of 5.7% from its current price of $12.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 12.14% downside risk from its current price of $12.52.
Fair Value
-
According to the consensus of 16 analysts, Dentsply Sirona, Inc. has 5.7% upside to fair value with a price target of $13.23 per share.
XRAY vs. S&P 500
-
Over the past 5 trading days, Dentsply Sirona, Inc. has underperformed the S&P 500 by -9.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dentsply Sirona, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dentsply Sirona, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Dentsply Sirona, Inc. reported revenues of $904M.
Earnings Growth
-
Dentsply Sirona, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Dentsply Sirona, Inc. reported earnings per share of -$2.14.
Enterprise value:
4.6B
EV / Invested capital:
--
Price / LTM sales:
0.69x
EV / EBIT:
17.03x
EV / Revenue:
1.27x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
57.69x
Price / Operating cash flow:
31.20x
Enterprise value / EBITDA:
7.46x
Gross Profit (TTM):
$1.9B
Return On Assets:
-14.61%
Net Income Margin (TTM):
-24.31%
Return On Equity:
-44.58%
Return On Invested Capital:
-20.14%
Operating Margin:
5.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.9B | $3.9B | $3.6B | $951M | $904M | |
| Gross Profit | $2.1B | $2B | $1.9B | $495M | $441M | |
| Operating Income | $306M | $264M | $271M | $67M | $49M | |
| EBITDA | $642M | $610M | $619M | $156M | $142M | |
| Diluted EPS | -$1.01 | -$2.07 | -$4.43 | -$2.46 | -$2.14 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.9B | $1.9B | $1.9B | $2.1B | |
| Total Assets | $9.3B | $7.5B | $7.2B | $6.6B | $5.7B | |
| Current Liabilities | $1.2B | $1.3B | $1.2B | $1.5B | $1.4B | |
| Total Liabilities | $4.2B | $3.9B | $3.8B | $4.1B | $4.2B | |
| Total Equity | $5.1B | $3.6B | $3.4B | $2.5B | $1.5B | |
| Total Debt | $2.2B | $2.1B | $2.1B | $2.3B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $359M | $534M | $221M | $141M | $79M | |
| Cash From Investing | -$98M | -$160M | -$144M | -$47M | -$36M | |
| Cash From Financing | -$340M | -$392M | -$19M | -$79M | -$36M | |
| Free Cash Flow | $218M | $365M | $80M | $98M | $40M | |
XRAY
Sector
Market Cap
$2.5B
$25.2M
Price % of 52-Week High
64.97%
49.83%
Dividend Yield
5.11%
0%
Shareholder Yield
2.93%
-1.77%
1-Year Price Total Return
-34.04%
-21.9%
Beta (5-Year)
1.012
0.499
Dividend yield:
5.11%
Annualized payout:
$0.64
Payout ratio:
13.5%
Growth streak:
6 years
Technicals
8-day SMA
Sell
Level
$13.07
200-day SMA
Sell
Level
$13.57
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$12.79
Relative Strength Index (RSI14)
Sell
Level
48.80
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-69.3111
50-day SMA
Buy
Level
$12.16
MACD (12, 26)
Buy
Level
1.77
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.215)
Sell
CA Score
(Annual)
Level (-0.5445)
Buy
Beneish M-Score
(Annual)
Level (-3.9157)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.124)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.
Stock Forecast FAQ
In the current month, XRAY has received 2 Buy ratings 14 Hold ratings, and 0 Sell ratings. The XRAY average analyst price target in the past 3 months is $13.23.
-
Where Will Dentsply Sirona, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dentsply Sirona, Inc. share price will rise to $13.23 per share over the next 12 months.
-
What Do Analysts Say About Dentsply Sirona, Inc.?
Analysts are divided on their view about Dentsply Sirona, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dentsply Sirona, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Dentsply Sirona, Inc.'s Price Target?
The price target for Dentsply Sirona, Inc. over the next 1-year time period is forecast to be $13.23 according to 16 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is XRAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dentsply Sirona, Inc. is a Hold. 14 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of XRAY?
You can purchase shares of Dentsply Sirona, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dentsply Sirona, Inc. shares.
-
What Is The Dentsply Sirona, Inc. Share Price Today?
Dentsply Sirona, Inc. was last trading at $12.54 per share. This represents the most recent stock quote for Dentsply Sirona, Inc.. Yesterday, Dentsply Sirona, Inc. closed at $12.52 per share.
-
How To Buy Dentsply Sirona, Inc. Stock Online?
In order to purchase Dentsply Sirona, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get XRAY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XRAY
Sector
P/E ratio
--
23.30x
PEG ratio
-0.02x
-0.01x
P/B ratio
1.69x
1.78x
Price / LTM sales
0.69x
1.55x
Growth Metrics
XRAY
Sector
Revenue growth
-4.94%
3.69%
Earnings growth
12.91%
9.95%
Revenue (5-year growth)
-1.2%
6.38%
Earnings forecast
$0.29
-$0.19
Profitability
XRAY
Sector
Profitability FY 2024
$2B
$2.6M
Return on invested capital
-20.14%
-33.25%
Return on assets
-14.61%
-29.67%
Return on equity
-44.58%
-38.66%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
XRAY
Sector
Total cash
$363M
$25.1M
Short term investments
--
$24M
Total assets
$5.8B
$72.5M
Long term debt
$2.5B
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
32
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Sell
49
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
73
HYMC alert for Feb 21
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Buy
62
OMC alert for Feb 21
Omnicom Group, Inc. [OMC] is up 2.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
